New inhaled drug tested for severe lung failure
NCT ID NCT07558538
First seen May 02, 2026 · Last updated May 15, 2026 · Updated 3 times
Summary
This early-stage trial will test the safety of a single inhaled dose of a lab-made protein (rhKGF-2) in 24 adults with moderate-to-severe ARDS who are on a breathing machine. Participants will receive either the study drug or standard care alone, and be monitored for 28 days for side effects and signs of lung improvement. The goal is to see if the drug is safe enough for further testing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARDS (ACUTE RESPIRATORY DISTRESS SYNDROME) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ShanghaiZhongshan
Shanghai, Shanghai Municipality, 200000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.